Alexandria, VA (March 3, 2026) — The AMCP Research Institute announced the launch of a new medication therapy management (MTM) health care improvement initiative designed to assess and manage modifiable risk factors for dementia in asymptomatic, middle-aged adults. The initiative is supported by a generous grant from Lilly and aims to address critical gaps in the identification and intervention of early dementia risk.
An estimated 6.7 million Americans aged 65 and older were living with Alzheimer’s disease in 2023, a number projected to double over the next 30 years. Research suggests that addressing modifiable risk factors, such as cardiovascular health, hearing loss, and lifestyle factors, could prevent or delay up to 45% of dementia cases. Despite this evidence, these risk factors are not routinely assessed or managed in adults during midlife, when intervention may have the greatest long-term impact.
The MTM Midlife Initiative to Navigate Dementia Risk (MTM-MIND) will leverage the expertise of MTM pharmacists to assess dementia risk in patients aged 40 to 60 years and provide education, referrals, and care coordination aligned with the Lancet Commission on dementia risk reduction. The initiative includes a payer-driven policy framework, pharmacist training materials, patient-facing Dementia Risk Report Cards, and education resources for patients and providers.
“Dementia does not begin at diagnosis—it develops over decades, often without symptoms,” said Susan Cantrell, RPh, CAE, CEO of AMCP. “By assessing and managing modifiable risk factors in asymptomatic, middle-aged adults, pharmacists can play a vital role in changing the trajectory of disease before cognitive decline begins. This initiative reflects AMCP’s commitment to advancing proactive, team-based care that improves long-term patient outcomes.”
“This initiative underscores the significance and real-world impact of the AMCP Research Institute’s work in advancing patient-centered care,” said Cate Lockhart, PharmD, PhD, Chief Science Officer of AMCP. “We are proud to partner with Lilly in support of our shared mission to optimize the use of medicines and improve patient outcomes.”
“While dementia care has traditionally been reactive, initiatives like MTM‑MIND recognize that risk factors can be identified and addressed well before symptoms appear,” said Jessie Fahrbach, MD, senior vice president, Global Medical Affairs, Lilly Neuroscience. “Partnering with the AMCP Research Institute helps shift care toward early, proactive intervention—empowering pharmacists to influence long-term brain health for millions.”
The 18-month initiative, led by Pam Pawloski, PharmD, BCOP, FCCP, AMCP Principal Research Scientist, will be implemented in collaboration with experts in Alzheimer’s disease research, managed care, data science, and pharmacy leadership, as well as HealthPartners and the Patient Advocate Foundation. Outcomes will include the proportion of MTM visits incorporating dementia risk assessment, changes in identified risk factors, and evaluation of implementation and sustainability using established frameworks such as RE-AIM and the Program Sustainability Framework.
Findings from the initiative will be disseminated through peer-reviewed publications, conference presentations, webinars, interest groups and stakeholder briefings to support scalability and broader adoption across health care systems.
About AMCP
AMCP is the professional association leading the way to help patients get the medications they need at a cost they can afford. AMCP’s diverse membership of pharmacists, physicians, nurses, biopharmaceutical professionals, and other stakeholders leverage their specialized expertise in clinical evidence and economics to optimize medication benefit design and population health management and help patients access cost-effective and safe medications and other drug therapies. AMCP members improve the lives of nearly 300 million Americans served by private and public health plans, pharmacy benefit management firms, and emerging care models.
About the AMCP Research Institute
Building on AMCP's proven track record in research through BBCIC, AMCP Research Institute (ARI) expands AMCP research horizons to encompass comprehensive studies, including cost analyses and policy support. ARI aims to elevate AMCP's mission, drive policy, and enhance member value by delivering robust, unbiased research that empowers practitioners and shapes the future of managed care pharmacy.
Media Contact:
Jim Cooney
Director, Marketing Operations & Growth
@email | 703-684-2652
AMCP offers a wide variety of educational opportunities, from events and webinars to online training.
